Illumina, Inc. (NASDAQ:ILMN) Receives $199.12 Average Price Target from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned a consensus rating of “Hold” from the eighteen ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $199.1250.

Several analysts recently commented on ILMN shares. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Stifel Nicolaus boosted their target price on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. TD Cowen raised their price objective on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st.

Insider Activity at Illumina

In other news, Director Keith Meister sold 119,501 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares in the company, valued at approximately $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,062,465 shares of company stock valued at $436,589,802 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in the stock. HighPoint Advisor Group LLC increased its stake in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the period. Elevation Wealth Partners LLC boosted its stake in shares of Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the period. Meeder Advisory Services Inc. grew its holdings in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares in the last quarter. Gabelli Funds LLC increased its stake in Illumina by 2.0% during the 1st quarter. Gabelli Funds LLC now owns 5,000 shares of the life sciences company’s stock worth $616,000 after buying an additional 100 shares during the period. Finally, MCF Advisors LLC lifted its holdings in Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN opened at $208.21 on Friday. The business has a fifty day simple moving average of $201.17 and a 200-day simple moving average of $163.08. The firm has a market cap of $31.44 billion, a PE ratio of 38.85, a P/E/G ratio of 2.93 and a beta of 1.46. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $231.81.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina will post 5.36 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.